CCIA
VRTX icon

Campbell & Co Investment Adviser’s Vertex Pharmaceuticals VRTX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,580
Closed -$2.49M – 1380
2026
Q1 		$2.49M Sell
5,580
-4,278
-43% -$1.99M 0.14% 218
2025
Q4 		$4.47M Buy
9,858
+7,835
+387% +$3.38M 0.21% 120
2025
Q3 		$792K Buy
+2,023
New +$845K 0.06% 520
2024
Q4 		– Sell
-1,215
Closed -$565K – 1396
2024
Q3 		$565K Sell
1,215
-288
-19% -$138K 0.04% 659
2024
Q2 		$704K Buy
1,503
+509
+51% +$221K 0.06% 514
2024
Q1 		$416K Sell
994
-4,394
-82% -$1.86M 0.04% 783
2023
Q4 		$2.19M Buy
5,388
+3,206
+147% +$1.18M 0.2% 109
2023
Q3 		$759K Buy
2,182
+764
+54% +$267K 0.09% 365
2023
Q2 		$499K Buy
1,418
+187
+15% +$63K 0.09% 439
2023
Q1 		$388K Sell
1,231
-2,829
-70% -$848K 0.07% 512
2022
Q4 		$1.17M Buy
+4,060
New +$1.24M 0.28% 71
2021
Q4 		– Sell
-1,900
Closed -$345K – 837
2021
Q3 		$345K Buy
+1,900
New +$371K 0.11% 328

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Campbell & Co Investment Adviser's VRTX Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 5,580 shares — an estimated $2.49M sold.

Campbell & Co Investment Adviser first reported a position in VRTX in Q3 2021 and held it in 12 quarters. The position peaked at $4.47M in Q4 2025. 1,014 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Campbell & Co Investment Adviser reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 5,580 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.49M.
  • Campbell & Co Investment Adviser first reported a position in Vertex Pharmaceuticals in Q3 2021 and held it in 12 quarters.
  • Campbell & Co Investment Adviser's Vertex Pharmaceuticals position peaked at $4.47M in Q4 2025.
  • 1,014 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.